Effectiveness of cyclooxygenase-2 inhibition in limiting abdominal aortic aneurysm progression in mice correlates with a differentiated smooth muscle cell phenotype

Journal of Cardiovascular Pharmacology

Volumn 60, Issue 6, 2012, Pages 520-529

  Mukherjee, Kamalika ^a   Gitlin, Jonathan M ^b   Loftin, Charles D ^c  

^a QUEEN S UNIVERSITY   (Canada)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c University of Kentucky   (United States)

Author keywords

abdominal aortic aneurysm; angiotensin II; cyclooxygenase 2; cyclooxygenase 2 inhibitor; smooth muscle cell phenotype

Indexed keywords

ALPHA ACTIN; ANGIOTENSIN II; CALPONIN; CELECOXIB; CYCLOOXYGENASE 2; DESMIN; MYOSIN HEAVY CHAIN; SMOOTHELIN; TRANSGELIN;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA RUPTURE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; ENZYME INHIBITION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER;

ANGIOTENSIN II; ANIMALS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; AORTIC RUPTURE; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHENOTYPE; PYRAZOLES; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; TIME FACTORS;

EID: 84871620365     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318270b968     Document Type: Article

References (36)

1. Anderson RN. Deaths: leading causes for 2000. Natl Vital Stat Rep. 2002;50:1-85.
2. Walton LJ, Franklin IJ, Bayston T, et al. Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation. 1999;100:48-54.
3. Baxter BT, Terrin MC, Dalman RL. Medical management of small abdominal aortic aneurysms. Circulation. 2008;117:1883-1889.
4. Vorp DA, Vande Geest JP. Biomechanical determinants of abdominal aortic aneurysm rupture. Arterioscler Thromb Vasc Biol. 2005;25:1558-1566.
5. Isselbacher EM. Thoracic and abdominal aortic aneurysms. Circulation. 2005;111:816-828.
6. Holmes DR, Wester W, Thompson RW, et al. Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms. J Vasc Surg. 1997;25:810-815.
7. Smith WL, DeWitt DL. Prostaglandin endoperoxide H synthases-1 and-2. Adv Immunol. 1996;62:167-215.
8. King VL, Trivedi DB, Gitlin JM, et al. Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol. 2006;26: 1137-1143.
9. Gitlin JM, Trivedi DB, Langenbach R, et al. Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. Cardiovasc Res. 2007;73:227-236.
10. Wang M, Lee E, Song W, et al. Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation. 2008;117:1302-1309.
11. Ailawadi G, Moehle CW, Pei H, et al. Smooth muscle phenotypic modulation is an early event in aortic aneurysms. J Thorac Cardiovasc Surg. 2009;138:1392-1399.
12. Fetalvero KM, Shyu M, Nomikos AP, et al. The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway. Am J Physiol Heart Circ Physiol. 2006;290: H1337-H1346.
13. Clement N, Glorian M, Raymondjean M, et al. PGE2 amplifies the effects of IL-1beta on vascular smooth muscle cell de-differentiation: a consequence of the versatility of PGE2 receptors 3 due to the emerging expression of adenylyl cyclase 8. J Cell Physiol. 2006;208:495-505.
14. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000;105:1605-1612.
15. Saraff K, Babamusta F, Cassis LA, et al. Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003; 23:1621-1626.
16. Chai S, Chai Q, Danielsen CC, et al. Overexpression of hyaluronan in the tunica media promotes the development of atherosclerosis. Circ Res. 2005;96:583-591.
17. Wang YX, Martin-McNulty B, da Cunha V, et al. Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. Circulation. 2005;111:2219-2226.
18. Zhang Y, Naggar JC, Welzig CM, et al. Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK. Arterioscler Thromb Vasc Biol. 2009;29:1764-1771.
19. Kristo F, Hardy GJ, Anderson TJ, et al. Pharmacological inhibition of BLT1 diminishes early abdominal aneurysm formation. Atherosclerosis. 2009;210:107-113.
20. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84:767-801.
21. Zhu L, Vranckx R, Khau Van Kien P, et al. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet. 2006;38:343-349.
22. Guo DC, Pannu H, Tran-Fadulu V, et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet. 2007;39:1488-1493.
23. Pannu H, Tran-Fadulu V, Papke CL, et al. MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II. Hum Mol Genet. 2007;16:2453-2462.
24. Huang J, Davis EC, Chapman SL, et al. Fibulin-4 deficiency results in ascending aortic aneurysms: a potential link between abnormal smooth muscle cell phenotype and aneurysm progression. Circ Res. 2010;106: 583-592.
25. Kolodgie FD, Burke AP, Farb A, et al. Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion. Arterioscler Thromb Vasc Biol. 2002;22:1642-1648.
26. Riessen R, Wight TN, Pastore C, et al. Distribution of hyaluronan during extracellular matrix remodeling in human restenotic arteries and ballooninjured rat carotid arteries. Circulation. 1996;93:1141-1147.
27. Evanko SP, Johnson PY, Braun KR, et al. Platelet-derived growth factor stimulates the formation of versican-hyaluronan aggregates and pericellular matrix expansion in arterial smooth muscle cells. Arch Biochem Biophys. 2001;394:29-38.
28. Lee MY, Garvey SM, Baras AS, et al. Integrative genomics identifies DSCR1 (RCAN1) as a novel NFAT-dependent mediator of phenotypic modulation in vascular smooth muscle cells. Hum Mol Genet. 2010;19: 468-479.
29. Sterpetti AV, Feldhaus RJ, Schultz RD, et al. Identification of abdominal aortic aneurysm patients with different clinical features and clinical outcomes. Am J Surg. 1988;156:466-469.
30. Brady AR, Thompson SG, Fowkes FG, et al. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation. 2004;110:16-21.
31. Johnsen SH, Forsdahl SH, Singh K, et al. Atherosclerosis in abdominal aortic aneurysms: a causal event or a process running in parallel? The Tromso study. Arterioscler Thromb Vasc Biol. 2010;30: 1263-1268.
32. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365:475-481.
33. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: population based nested case-control analysis. BMJ. 2005;330:1366.
34. McGettigan P, Henry D. Cardiovascular risk with non-steroidal antiinflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8:e1001098.
35. Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008;117:2104-2113.
36. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004; 351:1709-1711.